Latest news with #BioVie
Yahoo
6 days ago
- Health
- Yahoo
BioVie Highlighted ADDRESS-LC Phase 2 Trial Design Exploring Bezisterim for the Treatment of Neurological Symptoms of Long COVID at Keystone Symposia on Long COVID and Other Post-Acute Infection Syndromes
ADDRESS-LC trial is now enrolling patients with Long COVID-related fatigue and cognitive impairment at sites across the U.S. CARSON CITY, Nev., Aug. 13, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) ('BioVie' or the 'Company'), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced that a poster highlighting the design and enrichment strategy of its ongoing Phase 2 ADDRESS-LC trial will be presented at the Keystone Symposia on Long COVID and Other Post-Acute Infection Syndromes, held August 10–13 in Santa Fe, New Mexico. Long COVID is now recognized as a leading neurological condition that has affected an estimated 400 million individuals worldwide,1,2 .The Centers for Disease Control has reported that 6.9% of adults in the United States (more than 18 million individuals) currently or previously had long COVID.3 The neurological symptoms such as persistent cognitive dysfunction and fatigue can last for years and currently there are no FDA-approved treatment options.2,4 ADDRESS-LC (NCT06847191; is currently-enrolling participants for a phase 2, multicenter, double-blind, randomized, placebo-controlled, 16-week study evaluating the efficacy, safety, and tolerability of bezisterim in adult participants with Long COVID who are enriched for cognitive impairment and fatigue. The Phase 2 study is fully funded by a grant from the U.S. Department of Defense (DOD). Bezisterim is an anti-inflammatory agent being developed for Long COVID and other neurodegenerative diseases including Alzheimer's disease (AD) and Parkinson's disease (PD), in which TLR-driven inflammation contributes to cognitive decline. It has been shown to inhibit both TLR4-induced signaling and inflammatory NF-κB signaling,4 and is orally available, not immunosuppressive, and crosses the blood-brain barrier.5,6 In clinical trials of AD and PD, bezisterim has demonstrated a favorable safety and tolerability profile. "The ADDRESS-LC trial was designed with input from Long COVID patients with the goal of helping to address the tremendous unmet needs of this community," said Penelope Markham, PhD, Senior Vice President of BioVie's Liver Disease and Long COVID Programs, who will be presenting the design. "Ongoing neuroinflammation has been observed in many patients with Long COVID, and BioVie leveraged its experience in studying other neurodegenerative diseases characterized by inflammation to create a unique trial that will both rigorously evaluate bezisterim in patients and add to our understanding of Long COVID pathology as a whole'. The ADDRESS-LC trial features a novel design informed by direct input from clinicians and patients, incorporating pragmatic elements to enhance relevance and feasibility. The study employs an enrichment strategy to increase the likelihood of signal detection and stratifies participants by symptom duration (<2 years or ≥2 years) to account for potential development of refractory symptoms, as well as by age (18–45 or 46–64) to address age-related differences in cognition. Key endpoints include the change in performance on a bespoke Cogstate Cognitive Battery, an objective tool designed to assess bezisterim's potential to improve neurocognitive symptoms such as cognitive impairment associated with Long COVID. Details for the oral and poster presentations are as follows: Oral Presentation and Poster Details: Title: A Phase 2 Trial Designed to Enhance Signal Detection in an Evaluation of Bezisterim (NE3107) For the Treatment of Neurological Symptoms of Long COVID Symposia Spotlight: 2:15pm-4:30pm (MT), Monday, August 11 Poster displayed from 7:30pm-10:00pm (MT), Tuesday August 12 Poster number: 2011 To learn more about ADDRESS-LC trial enrollment, visit About Bezisterim Bezisterim (NE3107) is an orally bioavailable, blood-brain barrier (BBB)-permeable modulator of inflammation and insulin-sensitizer. In addition, it is not immunosuppressive and has a low risk of drug-drug interaction. By binding to ERK and selectively modulating NFκB activation and TNF-α production, BioVie believes that bezisterim may offer clinical improvements in several disease indications, including Alzheimer's disease, Parkinson's disease and long COVID. In Parkinson's disease, BioVie is currently enrolling patients in the Phase 2 SUNRISE-PD clinical trial evaluating the safety and efficacy of bezisterim on motor and non-motor symptoms in patients who have not been treated with carbidopa/levodopa, with topline data expected in late 2025 or early 2026. A previous Phase 2 study of bezisterim in Parkinson's disease (NCT05083260) completed in 2022, and data presented at the AD/PD™ 2023 International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders in Gothenburg, Sweden in March 2023 showed significant improvements in 'morning on' symptoms and clinically meaningful improvement in motor control in patients treated with a combination of bezisterim and levodopa versus patients treated with levodopa alone, and no drug-related adverse events. In long COVID, bezisterim has the potential to reduce neurological symptoms including fatigue and cognitive dysfunction. Persistently circulating viral spike proteins are believed to trigger TLR-4 driven activation of NFκB and the subsequent expression of inflammatory cytokines (IL-6, TNF, IFNg). BioVIe's Phase 2 ADDRESS-LC study, is a randomized (1:1), placebo-controlled, multicenter trial in approximately 200 patients to evaluate the safety, tolerability and potential efficacy of 3 months of treatment with bezisterim to reduce the neurocognitive symptoms associated with long COVID, including difficulty concentrating or remembering things ('brain fog') and fatigue. In Alzheimer's disease, BioVie conducted and reported efficacy data on its Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate bezisterim in patients who have mild-to-moderate Alzheimer's disease (NCT04669028) in 2023. Results of a Phase 2 investigator-initiated trial (NCT05227820) showing bezisterim-treated patients experienced improved cognition and biomarker levels were presented at the Clinical Trials on Alzheimer's Disease (CTAD) annual conference in December 2022. An estimated six million Americans suffer from Alzheimer's disease. Terms of the Department of Defense Award The work is supported by the Assistant Secretary of Defense for Health Affairs endorsed by the Department of Defense, by a fully funded award in the amount of $13.13 million through the Peer-Reviewed Medical Research Program (PRMRP) under Award No. HT9425-24-1-0113. Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the Assistant Secretary of Defense for Health Affairs or the Department of Defense. About BioVie Inc. BioVie Inc. (NASDAQ: BIVI) is a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders (Alzheimer's disease, Parkinson's disease and long COVID) and advanced liver disease. In neurodegenerative disease, the Company's drug candidate bezisterim inhibits inflammatory activation of extracellular signal-regulated kinase and the transcription factor nuclear factor-κB, and the associated neuroinflammation and insulin resistance but not ERK and NFκB homeostatic functions (e.g., insulin signaling and neuron growth and survival). Both neuroinflammation and insulin resistance are drivers of AD and PD. Persistent systematic inflammation and neuroinflammation are key features in patients with neurological symptoms of long COVID. In liver disease, the Company's Orphan drug candidate BIV201 (continuous infusion terlipressin), with FDA Fast Track status, is being evaluated and discussed with guidance received from the FDA regarding the design of Phase 3 clinical testing of BIV201 for the reduction of further decompensation in participants with liver cirrhosis and ascites. The active agent is approved in the U.S. and in about 40 countries for related complications of advanced liver cirrhosis. For more information, visit Forward-Looking Statements This press release contains forward-looking statements, which may be identified by words such as "expect," "look forward to," "anticipate" "intend," "plan," "believe," "seek," "estimate," "will," "project" or words of similar meaning. Although BioVie Inc. believes such forward-looking statements are based on reasonable assumptions, it can give no assurance that its expectations will be attained. Actual results may vary materially from those expressed or implied by the statements herein due to the Company's ability to successfully raise sufficient capital on reasonable terms or at all, available cash on hand and contractual and statutory limitations that could impair our ability to pay future dividends, our ability to complete our pre-clinical or clinical studies and to obtain approval for our product candidates, our ability to successfully defend potential future litigation, changes in local or national economic conditions as well as various additional risks, many of which are now unknown and generally out of the Company's control, and which are detailed from time to time in reports filed by the Company with the SEC, including quarterly reports on Form 10-Q, reports on Form 8-K and annual reports on Form 10-K. BioVie Inc. does not undertake any duty to update any statements contained herein (including any forward-looking statements), except as required by law. REFERENCES Avitzur O. President's Column, 2022. American Academy of Neurology. Accessed June 16, 2025. Al-Aly Z, et al. Nat Med 2024;30:2148-2164. doi:10.1038/s41591-024-03173-6 Ford ND, Agedew A, Dalton AF, Singleton J, Perrine CG, Saydah S. Notes from the Field: Long COVID Prevalence Among Adults — United States, 2022. MMWR Morb Mortal Wkly Rep 2024;73:135–136. DOI: Davis HE, et al. EClinicalMedicine. 2021;38:101019. doi:10.1016/ Reading CL, et al. Neurodegener Dis Manag. 2021;11(4):289-298. doi:10.2217/nmt-2021-0022 Ahlem CN, et al. Int J Clin Exp Med. 2011;4(2):119-135. For Media Inquiries: Contact:Chuck PadalaManaging DirectorLifeSci Advisors, LLCchuck@ Contact:Melyssa WeibleManaging Partner, Elixir Health Public Relations Ph: +1 201-723-5705mweible@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
10-08-2025
- Business
- Associated Press
New to The Street to Air Show #683 on Bloomberg, Featuring BioVie, FLOKI, PetVivo, and NRx Pharmaceuticals
NEW YORK CITY, NY / ACCESS Newswire / August 9, 2025 / New to The Street, one of the nation's longest-running business television brands, will broadcast Show #683 on Bloomberg today at 6:30 PM EST. This week's episode features four dynamic companies making waves in healthcare, biotech, blockchain gaming, and sports partnerships: BioVie Inc., FLOKI, PetVivo Holdings, Inc., and NRx Pharmaceuticals, Inc. The program, airing as sponsored programming, will also mark the television commercial debut of FLOKI, introducing the fastest-growing Valhalla Game to Bloomberg's national audience. Pedro Vidal, Chief Relationship Officer of FLOKI, discusses how the FLOKI Trading Bot has become the leader on the BNB Chain, giving traders advanced, user-friendly tools to maximize opportunities in the crypto market. Vidal also highlights the Valhalla Game's explosive success, where assets acquired in-game can be used in the real world - a groundbreaking integration of gaming and blockchain utility. Gamers are already winning Vera tokens, with over 100,000 Veras minted to date. For more information, visit and Jonathan Javitt, Founder, Chairman, and CEO of NRx Pharmaceuticals (NASDAQ:NRXP), discusses the Company's recent Citizen Petition to the U.S. Food and Drug Administration (FDA) seeking the removal of benzethonium chloride from all forms of ketamine sold in the United States. Benzethonium chloride, a preservative with known toxicity, is no longer allowed in hand cleansers, topical antiseptics, and many ophthalmic products. NRx has developed a preservative-free ketamine formulation with three-year stability, filed a supporting patent, and is pursuing FDA approval, including a potential labeled indication for treating suicidal depression under the FDA Commissioner's National Priority Voucher Program. Cuong Do, President and CEO of BioVie Inc. (NASDAQ:BIVI), provides an update on two ongoing Phase 3 clinical trials for Bezisterim. The first trial targets newly diagnosed Parkinson's patients entering therapy for the first time - potentially making Bezisterim the first new therapy for Parkinson's disease in more than 50 years. The second trial focuses on long COVID, specifically how Bezisterim may alleviate brain fog and fatigue, conditions affecting an estimated 17 million Americans. Both trials are expected to deliver top-line data in the first half of 2026. John Lai, CEO of PetVivo Holdings, Inc. (NASDAQ:PETV), joins Chase Chamberlin, Managing Partner at Commonwealth, to discuss their strategic partnership in the thoroughbred horse racing industry. Together, they aim to advance equine wellness by introducing PetVivo's innovative SPRYNG™ with OsteoCushion™ Technology into elite racing circles, offering a natural solution to maintain joint health in performance horses. About New to The Street For over 16 years, New to The Street has broadcast weekly as sponsored programming on Bloomberg Television and Fox Business, conducting more than 2,000 interviews with leaders from public and private companies. The brand operates the largest and fastest-growing digital business channel, New to The Street TV on YouTube, with over 3.16 million subscribers, delivering all-business, no-ads content. As a complete media ecosystem, New to The Street combines long-form television interviews, short-form TV commercials, iconic outdoor billboards, and the largest digital business platform to deliver predictable media for companies seeking to share their stories with investors, customers, and global audiences. For more information about upcoming episodes and featured companies, visit: Media Contact: Grace Bongiorno New to The Street [email protected] SOURCE: New to The Street press release
Yahoo
08-08-2025
- Business
- Yahoo
BioVie Inc. Announces Pricing of $12 Million Public Offering
CARSON CITY, Nev., Aug. 07, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI, BIVIW), ('BioVie' or the 'Company'), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders, today announced the pricing of its underwritten public offering of 6,000,000 units, with each unit consisting of one share of common stock and one warrant (the 'Warrants') (or pre-funded units in lieu thereof, with each pre-funded unit consisting of one pre-funded warrant (the 'Pre-Funded Warrants') and one Warrant). Each unit is being sold to the public at a price of $2.00 per unit (and each pre-funded unit is being sold to the public at the public offering price of each unit less the $0.0001 per share nominal exercise price for each Pre-Funded Warrant). The gross proceeds to the Company from this offering are expected to be approximately $12 million, before deducting underwriting discounts and commissions and other estimated offering expenses. The Warrants included in the units and pre-funded units have been approved for listing on the Nasdaq Capital Market and are expected to commence trading under the symbol 'BIVIW' on August 8, 2025. Each Warrant will be immediately exercisable, will entitle the holder to purchase one share of common stock at an exercise price of $2.50 per share and will expire five years from the date of issuance. Each Pre-Funded Warrant will be immediately exercisable, will entitle the holder to purchase one share of common stock and may be exercised at any time until exercised in full. The common stock (or Pre-Funded Warrants in lieu thereof) and Warrants can only be purchased together in the offering but will be issued separately. The Company has granted the underwriter a 45-day option to purchase up to an additional 900,000 shares of common stock and/or Pre-Funded Warrants and/or Warrants, or any combination thereof, solely to cover over-allotments, if any, at the public offering price, less underwriting discounts and commissions. The Company intends to use the proceeds for working capital and general corporate purposes. The offering is expected to close on August 11, 2025, subject to satisfaction of customary closing conditions. ThinkEquity is acting as sole book-running manager for the offering. A registration statement on Form S-1, as amended (File No. 333-288525), relating to the securities was filed with the Securities and Exchange Commission ('SEC') and was declared effective on August 7, 2025. This offering is being made only by means of a preliminary prospectus forming a part of the registration statement and a final prospectus. The registration statement and the preliminary prospectus relating to the offering are available for free on the SEC's website at Copies of the final prospectus, when available, may be obtained from ThinkEquity, 17 State Street, 41st Floor, New York, New York 10004. The final prospectus will be filed with the SEC and will be available on the SEC's website located at This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About BioVie Inc. (NASDAQ: BIVI) is a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders Alzheimer's disease (AD) and Parkinson's disease (PD) and LongCovid (LC) and advanced liver disease. In neurodegenerative disease, the Company's drug candidate bezisterim inhibits inflammatory activation of extracellular signal-regulated kinase and the transcription factor, Nuclear factor- kB, and the associated neuroinflammation and insulin resistance but not ERK and NFkB homeostatic functions (e.g., insulin signaling and neuron growth and survival). Both neuroinflammation and insulin resistance are drivers of AD and PD. Persistent systematic inflammation and neuroinflammation are key features in patients with neurological symptoms of Long liver disease, the Company's Orphan drug candidate BIV201 (continuous infusion terlipressin), with FDA Fast Track status, is being evaluated and discussed with guidance received from the FDA regarding the design of Phase 3 clinical testing of BIV201 for the reduction of further decompensation in participants with liver cirrhosis and ascites. The active agent is approved in the U.S. and in about 40 countries for related complications of advanced liver cirrhosis. For more information, visit Forward Looking StatementsThis press release contains forward-looking statements, which may be identified by words such as "expect," "look forward to," "anticipate" "intend," "plan," "believe," "seek," "estimate," "will," "project" or words of similar meaning. Although BioVie Inc. believes such forward-looking statements are based on reasonable assumptions, it can give no assurance that its expectations will be attained. Actual results may vary materially from those expressed or implied by the statements herein and are subject to a variety of risks and uncertainties, including but not limited to: expectations regarding the completion of the proposed offering; the Company's ability to successfully raise sufficient capital on reasonable terms or at all; available cash on hand and contractual and statutory limitations that could impair our ability to pay future dividends; our ability to complete our pre-clinical or clinical studies and to obtain approval for our product candidates; our ability to successfully defend potential future litigation; and changes in local or national economic conditions. Various additional risks, many of which are now unknown and generally out of the Company's control, are detailed from time to time in reports filed by the Company with the SEC, including annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K. BioVie Inc. does not undertake any duty to update any statements contained herein (including any forward-looking statements), except as required by law. For Investor Relations Inquiries: Chuck Padala Managing Director, Investor Relations chuck@ For Media Relations Inquiries: Melyssa Weible Managing Partner, Elixir Health Public Relations mweible@
Miami Herald
12-07-2025
- Business
- Miami Herald
New to The Street Episode #678 to Air on Bloomberg TV Featuring Game-Changing Innovators in AI, Biotech, Blockchain, and Sustainability
Broadcast Premieres Saturday, July 12 at 6:30 PM EST on Bloomberg Television NEW YORK CITY, NY / ACCESS Newswire / July 12, 2025 / New to The Street, the leading multi-platform financial news series, announces its upcoming Bloomberg Television broadcast, airing Saturday, July 12 at 6:30 PM EST. Episode #678 showcases five transformative companies leading advancements across artificial intelligence, healthcare, sustainability, and blockchain. This dynamic lineup brings powerful insights from visionary leaders shaping the future of their respective industries. Featured Segments in Episode #678: Hapbee Technologies (OTCQB:HAPBF)NBA All-Star Jaylen Brown shares how Hapbee's groundbreaking wearable neurotech helps optimize sleep, recovery, and cognitive performance-without pharmaceuticals. The device uses proprietary low-frequency signals to emulate the effects of popular compounds, empowering users to choose how they feel, naturally and safely. Arrive AI (NASDAQ:ARAI)Live from Nasdaq MarketSite in Times Square, host Ana Berry interviews CEO Dan O'Toole and Chief Strategy Officer Neerav Shah as they unveil Arrive's secure smart mailbox technology. Phase 1 launches in healthcare and logistics; Phase 2 expands to every U.S. ZIP code. Arrive beat Amazon to the patent by four days, reinforcing its first-mover advantage in the $150B+ last-mile delivery sector. FLOKI (CRYPTO:FLOKI)Pedro Vidal, FLOKI's Community Relations Officer, discusses the explosive success of Valhalla, its play-to-earn metaverse game. As FLOKI expands across DeFi, NFTs, and blockchain gaming, its highly engaged global community cements it as one of crypto's most disruptive and culturally relevant brands. Learn more at BioVie Inc. (NASDAQ:BIVI)CEO Cuong Do and Chief Medical Officer Joseph Palumbo join Jane King to share meaningful updates on BioVie's advancement in clinical trials targeting Alzheimer's, Parkinson's, and Long COVID. BioVie is the only company to receive a federal grant to study Long COVID, and is currently enrolling patients in a 200‑person clinical trial. They also introduce Social Impact Partners, a nonprofit initiative to foster collaboration across the private, public, and government sectors in supporting Alzheimer's patients. The segment touches on promising new research around BioVie's investigational drug Bezisterim, which may reduce cellular "rust buildup"-a key contributor to aging. Initial findings suggest it could play a role in slowing the aging process. The Sustainable Green Team (OTC:SGTM)CEO Tony Raynor outlines how SGTM transforms organic landfill waste into premium garden and soil products. What began as a mulch and tree removal business is now a regenerative brand with Amazon-ready offerings and national retail ambitions. SGTM is on a mission to restore soil health across America. Learn more at This episode is presented as sponsored programming on Bloomberg Television, reaching more than 124 million households nationwide. Further distribution includes: New to The Street's YouTube channel with 3 million+ subscribersEarned media coverage across major networksIconic outdoor billboards in Times Square and major U.S. metros Sponsors for Episode #678 include MUSQ, and Arrive AI TV Commercials. Media Contact:Monica BrennanNew to The Street - Media RelationsMonica@ Watch & Learn More: SOURCE: New to The Street
USA Today
12-07-2025
- Business
- USA Today
New to The Street Episode #678 to Air on Bloomberg TV Featuring Game-Changing Innovators in AI, Biotech, Blockchain, and Sustainability
Broadcast Premieres Saturday, July 12 at 6:30 PM EST on Bloomberg Television New to The Street, the leading multi-platform financial news series, announces its upcoming Bloomberg Television broadcast, airing Saturday, July 12 at 6:30 PM EST. Episode #678 showcases five transformative companies leading advancements across artificial intelligence, healthcare, sustainability, and blockchain. This dynamic lineup brings powerful insights from visionary leaders shaping the future of their respective industries. Featured Segments in Episode #678: Hapbee Technologies (OTCQB:HAPBF) NBA All-Star Jaylen Brown shares how Hapbee's groundbreaking wearable neurotech helps optimize sleep, recovery, and cognitive performance-without pharmaceuticals. The device uses proprietary low-frequency signals to emulate the effects of popular compounds, empowering users to choose how they feel, naturally and safely. Arrive AI (NASDAQ:ARAI) Live from Nasdaq MarketSite in Times Square, host Ana Berry interviews CEO Dan O'Toole and Chief Strategy Officer Neerav Shah as they unveil Arrive's secure smart mailbox technology. Phase 1 launches in healthcare and logistics; Phase 2 expands to every U.S. ZIP code. Arrive beat Amazon to the patent by four days, reinforcing its first-mover advantage in the $150B+ last-mile delivery sector. FLOKI (CRYPTO:FLOKI) Pedro Vidal, FLOKI's Community Relations Officer, discusses the explosive success of Valhalla, its play-to-earn metaverse game. As FLOKI expands across DeFi, NFTs, and blockchain gaming, its highly engaged global community cements it as one of crypto's most disruptive and culturally relevant brands. Learn more at BioVie Inc. (NASDAQ:BIVI) CEO Cuong Do and Chief Medical Officer Joseph Palumbo join Jane King to share meaningful updates on BioVie's advancement in clinical trials targeting Alzheimer's, Parkinson's, and Long COVID. BioVie is the only company to receive a federal grant to study Long COVID, and is currently enrolling patients in a 200‑person clinical trial. They also introduce Social Impact Partners, a nonprofit initiative to foster collaboration across the private, public, and government sectors in supporting Alzheimer's patients. The segment touches on promising new research around BioVie's investigational drug Bezisterim, which may reduce cellular 'rust buildup'-a key contributor to aging. Initial findings suggest it could play a role in slowing the aging process. The Sustainable Green Team (OTC:SGTM) CEO Tony Raynor outlines how SGTM transforms organic landfill waste into premium garden and soil products. What began as a mulch and tree removal business is now a regenerative brand with Amazon-ready offerings and national retail ambitions. SGTM is on a mission to restore soil health across America. Learn more at This episode is presented as sponsored programming on Bloomberg Television, reaching more than 124 million households nationwide. Further distribution includes: New to The Street's YouTube channel with 3 million+ subscribers Earned media coverage across major networks Iconic outdoor billboards in Times Square and major U.S. metros Sponsors for Episode #678 include MUSQ, and Arrive AI TV Commercials. 'We're proud to deliver this high‑impact episode featuring leaders from five of the most innovative sectors,' said Vince Caruso, Co‑Founder and Executive Producer of New to The Street. 'This show exemplifies our mission to present breakthrough companies and ideas with credibility, scale, and reach.' Media Contact: Monica Brennan New to The Street – Media Relations Monica@ Watch & Learn More: SOURCE: New to The Street View the original press release on ACCESS Newswire
